Liana Moussatos


Liana Moussatos, Ph.D. has more than two decades of research and analytics in the emerging pharmaceuticals sector. Liana joined Wedbush in 2009, from Pacific Growth Equities (PacGrow), where she was a Senior Research Analyst. Her extensive knowledge in this space not only gives her historical perspective, but also deep insight with industry and scientific understanding. Prior to PacGrow, she worked with UBS Global Asset Management where she was Director and Portfolio Manager of the firm’s Global Biotech Funds. Previously, Liana was with Bristol Myers-Squibb where she was manager in University and Government Licensing, External Science and Technology, and she also worked with Sloan-Kettering Cancer Institute in the Office of Industrial Affairs and the National Cancer Institute in the Office of Technology Development.

Liana received a BS in Entomology and MS in Zoology and Biochemistry from Clemson University. She earned a Ph.D. in Plant Pathology from the University of California, Davis and completed a postdoctoral research fellowship in Cellular and Molecular Physiology at the Yale School of Medicine.


Liana’s Edge: Risk assessment and her ability to analyze regulatory catalysts that have the potential to affect the market.


  • Aimmune Therapeutics (AIMT)
  • Albireo Pharma Inc. (ALBO)
  • Allena Pharmaceuticals Inc. (ALNA)
  • Aqestive Therapeutics, Inc. (AQST)
  • Aravive, Inc. (ARAV)
  • Ascendis Pharma A/S (ASND)
  • Axcella Health Inc. (AXLA)
  • BioMarin Pharmaceuticals (BMRN)
  • Catabasis Pharmaceuticals (CATB)
  • Clearside Biomedical Inc. (CLSD)
  • Eiger BioPharmaceuticals (EIGR)
  • Global Blood Therapeutics (GBT)
  • Graybug Vision, Inc. (GRAY)
  • Intercept Pharmaceuticals (ICPT)
  • Immunic, Inc. (IMUX)
  • Kala Pharmaceuticals (KALA)
  • Lexicon Pharmaceuticals (LXRX)
  • Liquidia Technologies, Inc. (LQDA)
  • ObsEva SA (OBSV)
  • Omeros Corp. (OMER)
  • Pacira Biosciences Inc. (PCRX)
  • Regulus Therapeutics Inc. (RGLS)
  • Sangamo Therapeutics Inc. (SGMO)
  • United Therapeutics Corp (UTHR)
  • Verona Pharma PLC (VRNA)
  • Xoma Corp (XOMA)